Allergan's eyelash drug may expand options for some patients
The recent announcement by Allergan that its new eyelash-enhancing drug is moving toward approval has plastic surgeons looking forward to a cosmetic enhancement that some say will be quite popular with patients and could provide a nice boost to plastic surgery practices.
Allergan, based in Irvine, CA, recently announced that it intends to file a new drug application by the end of the third quarter of this year with the FDA for bimatoprost, a synthetic prostaglandin analog, as a treatment to stimulate eyelash growth.
Allergan has completed its clinical trial program demonstrating that its patented formulation of bimatoprost, when applied directly to the base of the eyelashes, results in -significant eyelash growth, says Scott Whitcup, MD, executive vice president of research and development at Allergan.
- Senators Hear How Two-Midnight Rule Harms Patients, Hospitals
- 3 Management Lessons from a Supermarket Debacle
- Medicare Advantage Carriers See 'No Choice' But to Accept Cuts
- Physicians to Appeal 'Docs v. Glocks' Ruling in FL
- IOM Identifies GME Problems, Calls for Finance Changes
- Revenue Cycles Get a Boost from Simple JPEG Files
- CA Fines 8 Hospitals for Medical Errors
- Healthcare Costs Start With What We Eat
- Centralizing the Revenue Cycle Protects the Bottom Line
- As Medicare Advantage Cuts Loom, Disagreement Over Program's Stability